GSK Breakout Trade – Clean Setup AheadPattern: Bullish breakout from descending wedge
Entry Zone: Around $4.83–$4.97
Stop Loss: Just below $4.70 (trendline + horizontal support)
Target: $5.18 (green resistance level)
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
40.75 MXN
68.60 B MXN
835.91 B MXN
2.01 B
About GSK plc
Sector
Industry
CEO
Emma N. Walmsley
Website
Headquarters
London
ISIN
US37733W2044
FIGI
BBG00JX0NSM0
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Related stocks
$GSKA potential "ABC" pattern has been located here at a level where two previous support levels were broken. Price is near the 11-2023 support level. Looking for a retracement here to two targets overtime.
GSK 1-2 wk swing IdeaNYSE:GSK has set of a daily trigger with a 5/10 ema crossover after a positive earnings report.
During my planning for this idea, I needed to zoom WAY out to the monthly chart in order to understand these levels a bit more. Screen shot of the monthly below:
It turns out that last week's close
GSKNot a recommendation. Held this for a while with very little movement, now GSK as started going up, div yield is over 3.3%
Long GSK - Euro Drug Hype Cycle approachesPlaying short term trade presuming positive news in a week or two.
Shares would return to the range highs near $37.00
Ex-Dividend Date later this week
GSK (GSK) Outperformed Market ReturnsIn the latest trading session, GSK (GSK) closed at $37.10, marking a +1.23% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.63% for the day. Elsewhere, the Dow gained 0.59%, while the tech-heavy Nasdaq added 0.39%.
Prior to today's trading, shares of the dru
GSK looking bullish! Buy volume at resistance at this point in the falling channel should help propel the price to an initial measured target if $47 which would be thr breakout point of an even bigger bullish macro setup.
GSK with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for GSK after a negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 80%.
Long Glaxo Smith Kline (NAS:GSK) looks very good risk returnUsing longer term Auction Market Theory to construct longer term meaningful #VolumeProfiles can sometimes provide exceptional risk reward setups.
One has just popped up in GSK according to my read anyway.
Now price has returned into the longer term Value Area there's a very good chance price will
$GSK: Weekly trend signalGreat reward to risk in this weekly chart setup in $GSK, worth a shot, you can probably play it with options to not allocate too much capital in this idea and have limited downside risk. An ITM put spread or some kind of Iron Butterfly OTM can both reap the passage of time profiting from Theta drop
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
GSK6023692
GlaxoSmithKline Capital Plc FRN 12-MAR-2027Yield to maturity
—
Maturity date
Mar 12, 2027
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043Yield to maturity
—
Maturity date
Mar 18, 2043
GSK6023695
GlaxoSmithKline Capital, Inc. 4.5% 15-APR-2030Yield to maturity
—
Maturity date
Apr 15, 2030
GSK6023693
GlaxoSmithKline Capital, Inc. 4.875% 15-APR-2035Yield to maturity
—
Maturity date
Apr 15, 2035
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038Yield to maturity
—
Maturity date
May 15, 2038
GSK6023691
GlaxoSmithKline Capital Plc 4.315% 12-MAR-2027Yield to maturity
—
Maturity date
Mar 12, 2027
US377373AH8
GlaxoSmithKline Capital Plc 3.375% 01-JUN-2029Yield to maturity
—
Maturity date
Jun 1, 2029
XS182282812
GlaxoSmithKline Capital Plc 1.25% 21-MAY-2026Yield to maturity
—
Maturity date
May 21, 2026
GX5B
GlaxoSmithKline Capital Plc 1.0% 12-SEP-2026Yield to maturity
—
Maturity date
Sep 12, 2026
XS255381776
GSK Capital BV 3.125% 28-NOV-2032Yield to maturity
—
Maturity date
Nov 28, 2032
XS293369275
GSK Capital BV 3.25% 19-NOV-2036Yield to maturity
—
Maturity date
Nov 19, 2036
See all GSK/N bonds
Curated watchlists where GSK/N is featured.
Female-led stocks: Who rules the world?
34 No. of Symbols
UK stocks: Best of British
28 No. of Symbols
See all sparks
Frequently Asked Questions
The current price of GSK/N is 715.00 MXN — it has increased by 0.85% in the past 24 hours. Watch GSK plc Sponsored ADR stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange GSK plc Sponsored ADR stocks are traded under the ticker GSK/N.
We've gathered analysts' opinions on GSK plc Sponsored ADR future price: according to them, GSK/N price has a max estimate of 1,260.24 MXN and a min estimate of 567.48 MXN. Watch GSK/N chart and read a more detailed GSK plc Sponsored ADR stock forecast: see what analysts think of GSK plc Sponsored ADR and suggest that you do with its stocks.
GSK/N stock is 2.83% volatile and has beta coefficient of 0.27. Track GSK plc Sponsored ADR stock price on the chart and check out the list of the most volatile stocks — is GSK plc Sponsored ADR there?
Today GSK plc Sponsored ADR has the market capitalization of 1.50 T, it has increased by 4.82% over the last week.
Yes, you can track GSK plc Sponsored ADR financials in yearly and quarterly reports right on TradingView.
GSK plc Sponsored ADR is going to release the next earnings report on Oct 29, 2025. Keep track of upcoming events with our Earnings Calendar.
GSK/N earnings for the last quarter are 23.19 MXN per share, whereas the estimation was 21.96 MXN resulting in a 5.58% surprise. The estimated earnings for the next quarter are 23.29 MXN per share. See more details about GSK plc Sponsored ADR earnings.
GSK plc Sponsored ADR revenue for the last quarter amounts to 199.10 B MXN, despite the estimated figure of 196.90 B MXN. In the next quarter, revenue is expected to reach 204.96 B MXN.
GSK/N net income for the last quarter is 36.16 B MXN, while the quarter before that showed 41.90 B MXN of net income which accounts for −13.71% change. Track more GSK plc Sponsored ADR financial stats to get the full picture.
Yes, GSK/N dividends are paid quarterly. The last dividend per share was 7.89 MXN. As of today, Dividend Yield (TTM)% is 4.08%. Tracking GSK plc Sponsored ADR dividends might help you take more informed decisions.
GSK plc Sponsored ADR dividend yield was 4.53% in 2024, and payout ratio reached 94.89%. The year before the numbers were 3.87% and 47.48% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 6, 2025, the company has 68.63 K employees. See our rating of the largest employees — is GSK plc Sponsored ADR on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GSK plc Sponsored ADR EBITDA is 223.94 B MXN, and current EBITDA margin is 26.18%. See more stats in GSK plc Sponsored ADR financial statements.
Like other stocks, GSK/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GSK plc Sponsored ADR stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GSK plc Sponsored ADR technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GSK plc Sponsored ADR stock shows the sell signal. See more of GSK plc Sponsored ADR technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.